Literature DB >> 16570187

The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population.

Bing Chen1, Wei-Xia Zhang, Wei-Min Cai.   

Abstract

AIM: To determine the phenotype and genotype of NAT2 in a Chinese population and study the influence of various NAT2 genotypes on the NAT2 activity.
METHODS: A reverse dot blot method was used to detect the genotype of NAT2 in 120 healthy Chinese subjects. All subjects were given a single dose of 500 mg sulphadimidine (SM(2)). The plasma concentration of SM(2) and acetyl-SM(2) (AcSM(2)) 6 h after administration was determined. Molar metabolic ratio (MR) was calculated by the ratio of AcSM(2) to AcSM(2)+SM(2).
RESULTS: Totals of 53 (44.2%), 47 (39.2%) and 20 (16.7%) subjects were homozygotes for wild type (wt/wt), heterozygotes for mutant (m/wt) and homozygotes for mutant (m/m), respectively. The MR of 120 subjects was 0.714+/-0.237. Twenty subjects (16.7%) were classified as poor metabolizers. All subjects in the m/m group were poor metabolizers. The MRs of the wt/wt, m/wt and m/m groups were 0.886+/-0.060, 0.719+/-0.089 and 0.246+/-0.105 (P<0.001), respectively. There was a significant difference between different NAT2 m/wt genotypes (P<0.001) and m/m genotypes (P<0.001). MR correlated well with NAT2 genotypes (r=0.947).
CONCLUSION: Various NAT2 genotypes have a significant impact on the metabolic activity of NAT2 in Chinese people.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570187     DOI: 10.1007/s00228-006-0110-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Prediction of metabolic activity from genotype: the gene-dose effect of N-acetyltransferase.

Authors:  P Meisel; D Arndt; E Scheuch; K J Klebingat; W Siegmund
Journal:  Ther Drug Monit       Date:  2001-02       Impact factor: 3.681

Review 2.  N-acetyltransferase.

Authors:  D A Evans
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

3.  A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid.

Authors:  C A Smith; M Wadelius; A C Gough; D J Harrison; C R Wolf; A Rane
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

4.  Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients.

Authors:  Masahiro Hiratsuka; Yukinaga Kishikawa; Yoh Takekuma; Masaki Matsuura; Kaori Narahara; Tomoko Inoue; Samar Ismail Hamdy; Naomi Endo; Junichi Goto; Michinao Mizugaki
Journal:  Drug Metab Pharmacokinet       Date:  2002       Impact factor: 3.614

5.  Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population.

Authors:  J A Agúndez; M Olivera; C Martínez; J M Ladero; J Benítez
Journal:  Pharmacogenetics       Date:  1996-10

6.  Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population.

Authors:  M Gross; T Kruisselbrink; K Anderson; N Lang; P McGovern; R Delongchamp; F Kadlubar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-08       Impact factor: 4.254

7.  Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology.

Authors:  H J Lin; C Y Han; B K Lin; S Hardy
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

8.  Correlation between acetylation phenotype and genotype in Chinese women.

Authors:  B Zhao; A Seow; E J Lee; H P Lee
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

9.  Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population.

Authors:  X M Xu; W D Jiang
Journal:  Zhongguo Yao Li Xue Bao       Date:  1990-09

10.  Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions.

Authors:  D W Hein; M A Doll; T D Rustan; R J Ferguson
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

View more
  9 in total

1.  Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes.

Authors:  Mark A Doll; Yu Zang; Timothy Moeller; David W Hein
Journal:  J Pharmacol Exp Ther       Date:  2010-04-29       Impact factor: 4.030

2.  Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3' untranslated regions.

Authors:  Yuanqi Zhu; J Christopher States; Yang Wang; David W Hein
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-02-02

3.  Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.

Authors:  David W Hein; Mark A Doll
Journal:  Pharmacogenomics       Date:  2011-11-17       Impact factor: 2.533

4.  Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature.

Authors:  Rika Yuliwulandari; Qomariyah Sachrowardi; Nao Nishida; Miwa Takasu; Lilian Batubara; Tri Panjiasih Susmiarsih; Jecti Teguh Rochani; Riyani Wikaningrum; Risa Miyashita; Taku Miyagawa; Abdul Salam Mudzakir Sofro; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2007-12-27       Impact factor: 3.172

5.  Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.

Authors:  Zhi-duo Hou; Zheng-yu Xiao; Yao Gong; Yu-ping Zhang; Qing Yu Zeng
Journal:  BMC Pharmacol Toxicol       Date:  2014-11-21       Impact factor: 2.483

6.  Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes.

Authors:  Mark A Doll; Raúl A Salazar-González; Srineil Bodduluri; David W Hein
Journal:  Acta Pharm Sin B       Date:  2017-06-07       Impact factor: 11.413

7.  Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.

Authors:  Bing Chen; Hao-Qiang Shi; Meihua Rose Feng; Xi-Han Wang; Xiao-Mei Cao; Wei-Min Cai
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

Review 8.  Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.

Authors:  David W Hein; Lori M Millner
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-11-03       Impact factor: 4.481

9.  Human arylamine N-acetyltransferase 2 genotype-dependent protein expression in cryopreserved human hepatocytes.

Authors:  Raúl A Salazar-González; Mark A Doll; David W Hein
Journal:  Sci Rep       Date:  2020-05-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.